The GLP-1 receptor/GIP receptor/GCGR triple agonist efocipegtrutide is presently under investigation in individuals with MASLD, and preclinical accounts of other dual and triple agonists that include GLP-1 receptor and GCGR agonism suggest that clinical studies in individuals with type 2 diabetes will follow [62, 63]. Here, GCGR is linked to type 2 diabetes mellitus.